Blood test could spot Parkinson’s years earlier
pharmaphorum
JUNE 19, 2024
An AI-powered blood test that may be able to predict Parkinson’s years before symptoms develop could allow earlier treatment and guide trials of new treatments
pharmaphorum
JUNE 19, 2024
An AI-powered blood test that may be able to predict Parkinson’s years before symptoms develop could allow earlier treatment and guide trials of new treatments
MedCity News
JUNE 19, 2024
Key questions that must be answered The post Putting Payers in the Driver’s Seat: How the New CMS Interoperability and Prior Authorization is Changing Healthcare appeared first on MedCity News.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
European Pharmaceutical Review
JUNE 19, 2024
A non-chemotherapy multi-drug therapy enabled complete remission in 38 percent of evaluable patients with aggressive B-cell lymphoma, a Phase Ib/II clinical trial shows. This was observed in individuals who had experienced a return of their cancer or who were unresponsive to standard treatments. Venetoclax, ibrutinib, prednisone, obinutuzumab, and lenalidomide (ViPOR) were used together in a treatment regimen in 50 patients with diffuse large B-cell lymphoma (DLBCL).
MedCity News
JUNE 19, 2024
Emphasize the development of team members of all roles with multiple options for various leadership interests. The post Leadership Ladders: A Practical Guide to Building the Next Generation of Nurse Managers appeared first on MedCity News.
Evolve Your Success
JUNE 19, 2024
Join us for a captivating conversation with Dr. Vishal Rekhala, a double board-certified interventional pain physician, as he unveils the cutting-edge advancements in pain management. Dr. Rekhala shares his expertise on innovative treatments like spinal cord stimulation, regenerative medicine injections, and ultrasound-guided injections, providing a thorough understanding of how these procedures are transforming patient care.
pharmaphorum
JUNE 19, 2024
Marea Therapeutics raises $190m for cardiometabolic pipeline, with Santa Ana Bio, Opthea, InduPro, Elion, and iOnctura also completing rounds
Pharma Rep Focus brings together the best content for pharma rep professionals from the widest variety of industry thought leaders.
pharmaphorum
JUNE 19, 2024
Sobi’s long-acting rVIII drug Altuvoct has been cleared for haemophilia A in the EU, with a label that spans all ages and any disease severity.
PharmaTimes
JUNE 19, 2024
The serious condition is responsible for approximately 11 million deaths worldwide every year
pharmaphorum
JUNE 19, 2024
Novo Nordisk has been affected by a third fire in a month, the latest involving an office building near its Copenhagen headquarters.
PharmaTimes
JUNE 19, 2024
Congenital melanocytic naevus syndrome can cover up to 80% of the bodies of children
Advertisement
Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.
Integrity Solutions
JUNE 19, 2024
Why are some salespeople uniquely successful? Do they have some special sales skills that others don’t? If your sales force is somewhat normal, just 20% are high performers. Imagine what a difference it would make if motivating sales teams was tied directly to sales training and increasing their ability develop stronger customer relationships and sell more.
Quantified
JUNE 19, 2024
Executive Summary Artificial Intelligence (AI) is revolutionizing the insurance industry, enhancing customer interactions, risk assessment, and operational efficiency. This report examines AI’s influence on underwriting, predictive analytics, customer service, regulatory compliance, certification training, and the benefits for insurance sales teams.
Pharmaceutical Commerce
JUNE 19, 2024
The latest news for pharma industry insiders.
pharmaphorum
JUNE 19, 2024
Amazon Pharmacy is expanding its subscription service for generic medicines, making it available to Medicare patients
Evolve Your Success
JUNE 19, 2024
Unlock the secrets of simplifying complex medical procedures and fast-track your career in the competitive medical sales industry. In this enlightening episode, we sit down with Josh Reynolds, the Area Vice President of Sales in the Southeast for OrthoFundamentals, to explore the innovative landscape of SI joint fusion. Discover how OrthoFundamentals is redefining industry standards with their streamlined processes and cutting-edge products.
PharmExec
JUNE 19, 2024
In an interview with Pharm Exec Associate Editor Don Tracy, Pedro Valencia, VP, Solid Tumor Pipeline Strategy & Execution, AbbVie, discusses using novel cancer biomarkers to develop potential first-in-class antibody drug conjugates (ADCs) and the promise that they offer.
Pharmaceutical Technology
JUNE 19, 2024
IBI-343 is under clinical development by Innovent Biologics and currently in Phase I for Solid Tumor.
PharmExec
JUNE 19, 2024
Approval of Skyrizi marks the first IL-23 specific inhibitor approved for both ulcerative colitis and Crohn disease of similar severity, according to AbbVie.
Advertisement
Clinical research has entered a new era, one that requires real-time analytics and visualization to allow trial leaders to work collaboratively and to develop, at the click of a mouse, deep insights that enable proactive study management. Learn how Revvity Signals helps drug developers deliver clinical trial data insights in real-time using a fast and flexible data and analytics platform to empower data-driven decision-making.
Pharmaceutical Technology
JUNE 19, 2024
Polaroid Therapeutics’ CEO suggests that pharma should partner with medtech to prevent antibiotic resistance in wound management.
Pharmaceutical Commerce
JUNE 19, 2024
Deal will target neurological diseases, featuring an initial payment of $42 million for Ascidian and up to $1.8 billion in milestone payments/royalties.
Pharmaceutical Technology
JUNE 19, 2024
Elraglusib is under clinical development by Actuate Therapeutics and currently in Phase II for Post-Essential Thrombocythemia Myelofibrosis (Post-ET MF).
PharmExec
JUNE 19, 2024
The platform will use machine-learning and generative AI to provide insurers with a variety of options and increase automation in their processes.
Advertisement
Planning on running clinical trials in Japan? How can you reliably supply these studies? Discover Catalent’s clinical supply packaging facility in Shiga, Japan. Strategically located between Tokyo and Osaka, and one of largest in Japan, this 6,000 square meter facility offers comprehensive services including primary and secondary clinical packaging and labelling, comparator sourcing, cold chain storage, local and global distribution, local language support and white glove service to support stud
Pharmaceutical Technology
JUNE 19, 2024
Nitronazine is under clinical development by Guangzhou Magpie Pharmaceutical and currently in Phase II for Amyotrophic Lateral Sclerosis.
PharmExec
JUNE 19, 2024
OncLive serves as the connection to oncology, including groundbreaking cancer news and interviews with top oncologists in multimedia formats.
Pharmaceutical Technology
JUNE 19, 2024
Ascidian has entered a research partnership and licensing agreement with Roche to develop RNA therapies for neurological diseases.
PharmExec
JUNE 19, 2024
OncLive serves as the connection to oncology, including groundbreaking cancer news and interviews with top oncologists in multimedia formats.
Advertisement
Clinical development organizations face a wide array of challenges when it comes to data, many of which can impact the operational effectiveness of their clinical trials. In this whitepaper, experts from Revvity Signals explore how solutions like TIBCO® Spotfire® enable better, more streamlined studies. The whitepaper also features a success story from Ambrx, a leading biopharmaceutical company, detailing how it has leveraged Spotfire to tackle data quality and collaboration challenges in clinic
Pharmacy Times
JUNE 19, 2024
Being able to communicate in a different language can improve treatment adherence and medication efficacy outcomes
Pharmaceutical Technology
JUNE 19, 2024
Adakitug is under clinical development by Bristol-Myers Squibb and currently in Phase II for Hormone-Sensitive Prostate Cancer.
PharmaTech
JUNE 19, 2024
PRAC is reviewing the risk of secondary malignancies in patients treated with CAR T-cell medicines.
Pharmaceutical Technology
JUNE 19, 2024
AbbVie has received FDA approval for SKYRIZI to treat adult patients with moderately to severely active ulcerative colitis.
Advertisement
When selecting a clinical supply provider, consideration often focuses upon the manufacturing, packaging, storage and distribution capabilities available that will, at face-value, be sufficient to meet the needs of the sponsor and their trial. However, there are human-based and knowledge-driven factors that are often overlooked that go beyond these basic physical capabilities and are integral to the development and delivery of high performing clinical supply chains.
Let's personalize your content